$1.77-0.02 (-1.12%)
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Annovis Bio, Inc. in the Healthcare sector is trading at $1.77. Wall Street consensus targets $12.50 (2 analysts), implying a +606.2% move over the next 12 months. The stock is currently near its 52-week low of $1.54, remaining 31.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label ...
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046. The company, which works on drugs for brain-related diseases, […]
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.